Luteolin as an anti-inflammatory and neuroprotective agent: A brief review

Brain Research Bulletin

Volumn 119, Issue , 2015, Pages 1-11

  Nabavi, Seyed Fazel ^a   Braidy, Nady ^b   Gortzi, Olga ^c   Sobarzo Sanchez, Eduardo ^d   Daglia, Maria ^e   Skalicka Woźniak, Krystyna ^f   Nabavi, Seyed Mohammad ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c TECHNOLOGICAL EDUCATIONAL INSTITUTE OF LARISSA   (Greece)

^d UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^e UNIVERSITY OF PAVIA   (Italy)

^f MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Alzheimer's disease; Flavonoid; Luteolin; Neurotoxicity; Oxidative stress

Indexed keywords

ANTIINFLAMMATORY AGENT; ESCULETIN; GLYCOSIDE; LUTEOLIN; NEUROPROTECTIVE AGENT; PYRANOSIDE;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; AUTISM; COGNITIVE DEFECT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; EPILEPSY; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; TRAUMATIC BRAIN INJURY; ANIMAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; LUTEOLIN; NEUROPROTECTIVE AGENTS;

EID: 84944079121     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2015.09.002     Document Type: Review

References (148)

1. Žemlička L., Fodran P., Lukeš V., Vagánek A., Slováková M., Staško A., Dubaj T., Liptaj T., Karabín M., Birošová L. Physicochemical and biological properties of luteolin-7-O-β--glucoside (cynaroside) isolated from Anthriscus sylvestris (L.) Hoffm. Monatsh. Chem. 2014, 145(8):1307-1318.
2. Ahmed T., Abdollahi M., Daglia M., Nabavi S.F., Nabavi S.M. Berberine and neurodegeneration: a review of literature. Pharmacol. Rep. 2015, 10.1016/j.pharep.2015.03.002.
3. Aksamitiene E., Achanta S., Kiyatkin A., Hoek J.B. Synergistic anti-tumor effect by a combination treatment with the dietary flavonoid luteolin and the chemotherapy drugs Tasigna or Adrucil in human pancreatic cancer cells. FASEB J. 2012, 26. 999.4.
4. Allen K.V., Pickering M.J., Zammitt N.N., Hartsuiker R.J., Traxler M.J., Frier B.M., Deary I.J. Effects of acute hypoglycemia on working memory and language processing in adults with and without type 1 diabetes. Diabetes Care 2015, 38(6):1108-1115.
5. Almahy H.A., Fouda H.A.R. Isolation of luteolin 8-c-β--glucopyranoside from the roots of Salvadora persica (Rutaceae). J. Curr. Chem. Pharm. Sci. 2013, 3(1):49-53.
6. Bai L., Xu X.L., Wang Q., Xu S.L., Ju W., Wang X., Chen W.S., He W.Y., Tang H., Lin Y. A superoxide-mediated mitogen-activated protein kinase phosphatase-1 degradation and c-Jun NH2-terminal kinase activation pathway for Luteolin-induced lung cancer cytotoxicity. Mol. Pharmacol. 2012, 81(4):549-555.
7. Bando Y., Nomura T., Bochimoto H., Murakami K., Tanaka T., Watanabe T., Yoshida S. Abnormal morphology of myelin and axon pathology in murine models of multiple sclerosis. Neurochem. Int. 2015, 81:16-27.
8. Barreira J.C., Dias M.I., Živković J., Stojković D., Soković M., Santos-Buelga C., Ferreira I.C. Phenolic profiling of Veronica spp. grown in mountain, urban and sandy soil environments. Food Chem. 2014, 163:275-283.
9. Baskar A.A., Ignacimuthu S., Michael G.P., Al Numair K.S. Cancer chemopreventive potential of luteolin-7-o-glucoside isolated from Ophiorrhiza mungos Linn. Nutr. Cancer 2011, 63(1):130-138.
10. Bertolotto A., Granieri L., Marnetto F., Valentino P., Sala A., Capobianco M., Malucchi S., Di Sapio A., Malentacchi M., Matta M., Caldano M. Biological monitoring of IFN-beta therapy in multiple sclerosis. Cytokine Growth Factor Rev. 2015, 26(2):241-248.
11. Bove J., Prou D., Perier C., Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2005, 2(3):484-494.
12. Bravo L. Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr. Rev. 1998, 56(11):317-333.
13. Broadstock M., Doughty C., Eggleston M. Systematic review of the effectiveness of pharmacological treatments for adolescents and adults with autism spectrum disorder. Autism 2007, 11(4):335-348.
14. Brooks J.C., Strauss D.J., Shavelle R.M., Paculdo D.R., Hammond F.M., Harrison-Felix C.L. Long-term disability and survival in traumatic brain injury: results from the National Institute on Disability and Rehabilitation Research Model Systems. Arch. Phys. Med. Rehabil. 2013, 94(11):2203-2209.
15. Cai X.T., Ye T.M., Liu C., Lu W.G., Lu M., Zhang J., Wang M., Cao P. Luteolin induced G2 phase cell cycle arrest and apoptosis on non-small cell lung cancer cells. Toxicol. In Vitro 2011, 25(7):1385-1391.
16. Carranza M., Carranza M., Snyder M.R., Shaw J.D., Zesiewicz T.A., Snyde M.R. Parkinson's Disease. A Guide to Medical Treatment 2013, SEEd.
17. Chen H.Q., Jin Z.Y., Wang X.J., Xu X.M., Deng L., Zhao J.W. Luteolin protects dopaminergic neurons from inflammation-induced injury through inhibition of microglial activation. Neurosci. Lett. 2008, 448(2):175-179.
18. Cheng H.Y., Hsieh M.T., Tsai F.S., Wu C.R., Chiu C.S., Lee M.M., Xu H.X., Zhao Z.Z., Peng W.H. Neuroprotective effect of luteolin on amyloid β protein (25-35)-induced toxicity in cultured rat cortical neurons. Phytother. Res. 2010, 24(S1):S102-S108.
19. Choi S.M., Kim B.C., Cho Y.H., Choi K.H., Chang J., Park M.S., Kim M.K., Cho K.H., Kim J.K. Effects of flavonoid compounds on beta-amyloid-peptide-induced neuronal death in cultured mouse cortical neurons. Chonnam Med. J. 2014, 50(2):45-51.
20. Coleta M., Campos M.G., Cotrim M.D., de Lima T.C.M., da Cunha A.P. Assessment of luteolin (3',4',5,7-tetrahydroxyflavone) neuropharmacological activity. Behav. Brain Res. 2008, 189(1):75-82.
21. Corcoran M.P., McKay D.L., Blumberg J.B. Flavonoid basics: chemistry, sources, mechanisms of action, and safety. J. Nutr. Gerontol. Geriatr. 2012, 31(3):176-189.
22. Cordaro M., Impellizzeri D., Paterniti I., Bruschetta G., Siracusa R., De Stefano D., Cuzzocrea S., Esposito E. Neuroprotective effects of Co-ultraPEALut on secondary inflammatory process and autophagy involved in traumatic brain injury. J. Neurotrauma 2014, 10.1089/neu.2014.3460.
23. Daglia M., Di Lorenzo A., Nabavi S.F., Talas Z.S., Nabavi S.M. Polyphenols: well beyond the antioxidant capacity: gallic acid and related compounds as neuroprotective agents: you are what you eat!. Curr. Pharm. Biotechnol. 2014, 15(4):362-372.
24. De Paiva S., Figueiredo M., Kaplan M. Estudo fitoquímico de Plumbago auriculata Lam. Rev. Fitos Eletrôn. 2013, 1(02).
25. Di Domenico F., Barone E., Perluigi M., Butterfield D.A. Strategy to reduce free radical species in Alzheimer's disease: an update of selected antioxidants. Expert Rev. Neurother. 2015, 15(1):19-40.
26. Dirscherl K., Karlstetter M., Ebert S., Kraus D., Hlawatsch J., Walczak Y., Moehle C., Fuchshofer R., Langmann T. Luteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotective phenotype. J. Neuroinflammation 2010, 7:3-2094.
27. Donato F., de Gomes M.G., Goes A.T., Filho C.B., Del Fabbro L., Antunes M.S., Souza L.C., Boeira S.P., Jesse C.R. Hesperidin exerts antidepressant-like effects in acute and chronic treatments in mice: possible role of -arginine-NO-cGMP pathway and BDNF levels. Brain Res. Bull. 2014, 104:19-26.
28. El-Ansary A., Al-Ayadhi L. Neuroinflammation in autism spectrum disorders. J. Neuroinflammation 2012, 9:265.
29. El-Ansary A., Al-Ayadhi L. GABAergic/glutamatergic imbalance relative to excessive neuroinflammation in autism spectrum disorders. J. Neuroinflammation 2014, 11:189.
30. Elhawary S., Eltantawy M., Sleem A., Abdallah H., Mohamed N. Investigation of phenolic content and biological activities of Scabiosa atropurpurea L. World Appl. Sci. J. 2011, 15(3):311-317.
31. Fratiglioni L., Launer L.J., Andersen K., Breteler M.M., Copeland J.R., Dartigues J.F., Lobo A., Martinez-Lage J., Soininen H., Hofman A. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic diseases in the Elderly Research Group. Neurology 2000, 54(11 (Suppl. 5)):S10-S15.
32. Fries J.F. Aging, natural death, and the compression of morbidity. Bull. World Health Organ. 2002, 80(3):245-250.
33. Ghosh S., Chattopadhyay D., Mandal A., Kaity S., Samanta A. Bioactivity guided isolation of antiinflammatory, analgesic, and antipyretic constituents from the leaves of Pedilanthus tithymaloides (L.). Med. Chem. Res. 2013, 22(9):4347-4359.
34. Gu R., Wang Y., Long B., Kennelly E., Wu S., Liu B., Li P., Long C. Prospecting for bioactive constituents from traditional medicinal plants through ethnobotanical approaches. Biol. Pharm. Bull. 2013, 37(6):903-915.
35. Guo W.M., Kong E., Meydani M. Dietary polyphenols, inflammation, and cancer. Nutr. Cancer 2009, 61(6):807-810.
36. Guttmacher A.E., Collins F.S., Nussbaum R.L., Ellis C.E. Alzheimer's disease and Parkinson's disease. N. Engl. J. Med. 2003, 348(14):1356-1364.
37. Harwood M., Danielewska-Nikiel B., Borzelleca J.F., Flamm G.W., Williams G.M., Lines T.C. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem. Toxicol. 2007, 45(11):2179-2205.
38. Hendrie H.C. Epidemiology of dementia and Alzheimer's disease. Am. J. Geriatr. Psychiatry 1998, 6(2):S3-18.
39. Hu L.W., Yen J.H., Shen Y.T., Wu K.Y., Wu M.J. Luteolin modulates 6-hydroxydopamine-induced transcriptional changes of stress response pathways in PC12 cells. PLoS One 2014, 9(5):e97880.
40. Huynh J., Dawson D., Roberts D., Bentley-Lewis R. A systematic review of placental pathology in maternal diabetes mellitus. Placenta 2015, 36(2):101-114.
41. Ingkaninan K., Ijzerman A., Verpoorte R. Luteolin, a compound with adenosine a1 receptor-binding activity, and chromone and dihydronaphthalenone constituents from Senna siamea. J. Nat. Prod. 2000, 63(3):315-317.
42. Iratni R., Attoub S., Hassan A.H., Vanhoecke B., Gaben A.M., Bracke M., Al-Sultan M., Arafat K., Gespach C., Petroianu G. Inhibition of cell survival, tumor growth and histone deacetylase (hdac) activity by the dietary flavonoid luteolin in human epithelioid cancer cells. J. Thorac. Oncol. 2010, 5(5):S114.
43. Jang S.W., Liu X., Yepes M., Shepherd K.R., Miller G.W., Liu Y., Wilson W.D., Xiao G., Blanchi B., Sun Y.E., Ye K. A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(6):2687-2692.
44. Jansat J.M., Costa J., Salva P., Fernandez F.J., Martinez-Tobed A. Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers. J. Clin. Pharmacol. 2002, 42(12):1303-1310.
45. Jeon Y.W., Suh Y.J. Synergistic apoptotic effect of celecoxib and luteolin on breast cancer cells. Oncol. Rep. 2013, 29(2):819-825.
46. Jie L., Tian T., ShiXuan L., DeTian J., JinBo G., Yang T. Research on the synthesis of luteolin-chrome complex and its scavenging of DPPH free radical activity. Med. Plant 2014, 5(4):16-19.
47. Jing-fen L. Synthesis of luteolin Zn (II) and Cu (II) metal complexes and characterization of their electrochemical properties. Chem. World 2006, 3:3.
48. Johnson J.L., de Mejia E.G. Interactions between dietary flavonoids apigenin or luteolin and chemotherapeutic drugs to potentiate anti-proliferative effect on human pancreatic cancer cells, in vitro. Food Chem. Toxicol. 2013, 60:83-91.
49. Kang S.S., Lee J.Y., Choi Y.K., Kim G.S., Han B.H. Neuroprotective effects of flavones on hydrogen peroxide-induced apoptosis in SH-SY5Y neuroblostoma cells. Bioorg. Med. Chem. Lett. 2004, 14(9):2261-2264.
50. Kempuraj D., Madhappan B., Christodoulou S., Boucher W., Cao J., Papadopoulou N., Cetrulo C.L., Theoharides T.C. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br. J. Pharmacol. 2005, 145(7):934-944.
51. Kempuraj D., Tagen M., Iliopoulou B.P., Clemons A., Vasiadi M., Boucher W., House M., Wolfberg A., Theoharides T.C. Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell-dependent stimulation of Jurkat T cells. Br. J. Pharmacol. 2008, 155(7):1076-1084.
52. Kim J.S., Jobin C. The flavonoid luteolin prevents lipopolysaccharide-induced NF-kappa B signalling and gene expression by blocking I kappa B kinase activity in intestinal epithelial cells and bone-marrow derived dendritic cells. Immunology 2005, 115(3):375-387.
53. Kim A.K., Kim E.Y. Luteolin enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of Sk-Br3 human breast cancer. Pharm. Biol. 2012, 50(5):594.
54. Kim J.S., Kwon C.S., Son K.H. Inhibition of alpha-glucosidase and amylase by luteolin, a flavonoid. Biosci. Biotechnol. Biochem. 2000, 64(11):2458-2461.
55. Kim N.M., Kim J., Chung H.Y., Choi J.S. Isolation of luteolin 7-O-rutinoside and esculetin with potential antioxidant activity from the aerial parts of Artemisia montana. Arch. Pharm. Res. 2000, 23(3):237-239.
56. Kim M.J., Woo J.S., Kwon C.H., Kim J.H., Kim Y.K., Kim K.H. Luteolin induces apoptotic cell death through AIF nuclear translocation mediated by activation of ERK and p38 in human breast cancer cell lines. Cell Biol. Int. 2012, 36(4):339-344.
57. Kritas S.K., Saggini A., Varvara G., Murmura G., Caraffa A., Antinolfi P., Toniato E., Pantalone A., Neri G., Frydas S., Rosati M., Tei M., Speziali A., Saggini R., Pandolfi F., Cerulli G., Theoharides T.C., Conti P. Luteolin inhibits mast cell-mediated allergic inflammation. J. Biol. Regul. Homeost. Agents 2013, 27(4):955-959.
58. Kuhad A., Chopra K. Effect of sesamol on diabetes-associated cognitive decline in rats. Exp. Brain Res. 2008, 185(3):411-420.
59. Lee J.K., Kim S.Y., Kim Y.S., Lee W.H., Hwang D.H., Lee J.Y. Suppression of the TRIF-dependent signaling pathway of Toll-like receptors by luteolin. Biochem. Pharmacol. 2009, 77(8):1391-1400.
60. Lee M., Lin Y., Tsai P., Kandaswami C., Ke F., Hwang J., Lee P. Study of the effects of dietary flavonoids, luteolin and quercetin on the reversal of epithelial-mesenchymal transition in a431 epidermal cancer cells. Eur. J. Cancer 2011, 47:S115.
61. Lee E.J., Oh S.Y., Sung M.K. Luteolin exerts anti-tumor activity through the suppression of epidermal growth factor receptor-mediated pathway in MDA-MB-231 ER-negative breast cancer cells. Food Chem. Toxicol. 2012, 50(11):4136-4143.
62. Li J.F., Wang L.S., Bai H.Q., Yang B., Chen Z.G. Synthesis and structure characterization of novel luteolin derivatives. Chem. Nat. Compd. 2010, 46(5):716-718.
63. Lim D.Y., Cho H.J., Kim J., Nho C.W., Lee K.W., Park J.H.Y. Luteolin decreases IGF-II production and downregulates insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells. BMC Gastroenterol. 2012, 12.
64. Lin Y., Shi R., Wang X., Shen H.M. Luteolin, a flavonoid with potentials for cancer prevention and therapy. Curr. Cancer Drug Targets 2008, 8(7):634-646.
65. Lin C.W., Wu M.J., Liu I.Y.C., Su J.D., Yen J.H. Neurotrophic and cytoprotective action of luteolin in PC12Cells through ERK-dependent induction of Nrf2-driven HO-1 expression. J. Agric. Food Chem. 2010, 58(7):4477-4486.
66. Lin Y.S., Tsai P.H., Kandaswami C.C., Cheng C.H., Ke F.C., Lee P.P., Hwang J.J., Lee M.T. Effects of dietary flavonoids, luteolin, and quercetin on the reversal of epithelial-mesenchymal transition in A431 epidermal cancer cells. Cancer Sci. 2011, 102(10):1829-1839.
67. Lin L.C., Pai Y.F., Tsai T.H. Isolation of luteolin and luteolin-7-o-glucoside from Dendranthema morifolium ramat tzvel and their pharmacokinetics in Rats. J. Agric. Food Chem. 2015, 10.1021/jf505848z.
68. Liu R., Gao M., Qiang G.F., Zhang T.T., Lan X., Ying J., Du G.H. The anti-amnesic effects of luteolin against amyloid beta(25-35) peptide-induced toxicity in mice involve the protection of neurovascular unit. Neuroscience 2009, 162(4):1232-1243.
69. Liu Y., Tian X., Gou L.S., Sun L.Y., Ling X., Yin X.X. Luteolin attenuates diabetes-associated cognitive decline in rats. Brain Res. Bull. 2013, 94:23-29.
70. Lopez-Lazaro M. Distribution and biological activities of the flavonoid luteolin. Mini Rev. Med. Chem. 2009, 9(1):31-59.
71. Maroso M., Balosso S., Ravizza T., Liu J., Aronica E., Iyer A.M., Rossetti C., Molteni M., Casalgrandi M., Manfredi A.A., Bianchi M.E., Vezzani A. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat. Med. 2010, 16(4):413-U491.
72. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U. S. A. 1985, 82(12):4245-4249.
73. Mastrocola R., Restivo F., Vercellinatto I., Danni O., Brignardello E., Aragno M., Boccuzzi G. Oxidative and nitrosative stress in brain mitochondria of diabetic rats. J. Endocrinol. 2005, 187(1):37-44.
74. Matteo V., Esposito E. Biochemical and therapeutic effects of antioxidants in the treatment of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Curr. Drug Targets CNS Neurol. Disord. 2003, 2(2):95-107.
75. McDougle C.J., Carlezon W.A. Neuroinflammation and autism: toward mechanisms and treatments. Neuropsychopharmacology 2013, 38(1):241-242.
76. McPartland J., Volkmar F.R. Autism and related disorders. Neurobiol. Psychiatr. Disord. 2012, 106:407-418.
77. McVicar C.M., Ward M., Colhoun L.M., Guduric-Fuchs J., Bierhaus A., Fleming T., Schlotterer A., Kolibabka M., Hammes H.P., Chen M., Stitt A.W. Role of the receptor for advanced glycation endproducts (RAGE) in retinal vasodegenerative pathology during diabetes in mice. Diabetologia 2015, 58(5):1129-1137.
78. Middleton E., Kandaswami C., Theoharides T.C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol. Rev. 2000, 52(4):673-751.
79. Mousavi S.M., Niazmand S., Hosseini M., Hassanzadeh Z., Sadeghnia H.R., Vafaee F., Keshavarzi Z. Beneficial Effects of Teucrium polium and Metformin on diabetes-induced memory impairments and brain tissue oxidative damage in rats. Int. J. Alzheimers Dis. 2015, 493729.
80. Nabavi S.F., Nabavi S.M., Latifi A.M., Mirzaei M., Habtemariam S., Moghaddam A.H. Mitigating role of quercetin against sodium fluoride-induced oxidative stress in the rat brain. Pharm. Biol. 2012, 50(11):1380-1383.
81. Nabavi S.F., Nabavi S.M., Mirzaei M., Moghaddam A.H. Protective effect of quercetin against sodium fluoride induced oxidative stress in rat's heart. Food Funct. 2012, 3(4):437-441.
82. Nabavi S.F., Nabavi S.M., Moghaddam A.H., Naqinezhad A., Bigdellou R., Mohammadzadeh S. Protective effects of Allium paradoxum against gentamicin-induced nephrotoxicity in mice. Food Funct. 2012, 3(1):28-29.
83. Nabavi S.F., Nabavi S.M., Ebrahimzadeh M.A., Jafari N., Yazdanpanah S. Biological activities of freshwater algae, Spirogyra singularis Nordstedt. J. Aquat. Food Prod. Technol. 2013, 22(1):58-65.
84. Nabavi S.F., Nabavi S.M., Setzer N.W., Nabavi S.A., Nabavi S.A., Ebrahimzadeh M.A. Antioxidant and antihemolytic activity of lipid-soluble bioactive substances in avocado fruits. Fruits 2013, 68(03):185-193.
85. Nabavi S.F., Daglia M., Moghaddam A.H., Habtemariam S., Nabavi S.M. Curcumin and liver disease: from chemistry to medicine. Compr. Rev. Food Sci. Food Saf. 2014, 13(1):62-77.
86. Nabavi S.M., Daglia M., Moghaddam A.H., Nabavi S.F., Curti V. Tea consumption and risk of ischemic stroke: a brief review of the literature. Curr. Pharm. Biotechnol. 2014, 15(4):298-303.
87. Nabavi S.F., Russo G.L., Daglia M., Nabavi S.M. Role of quercetin as an alternative for obesity treatment: you are what you eat!. Food Chem. 2015, 179:305-310.
88. Nabavi S.F., Sureda A., Habtemariam S., Nabavi S.M. Ginsenoside Rd and ischemic stroke; a short review of literatures. J. Ginseng Res. 2015, 10.1016/j.jgr.2015.02.002.
89. Nordeen S.K., Bona B.J., Jones D.N., Lambert J.R., Jackson T.A. Endocrine disrupting activities of the flavonoid nutraceuticals luteolin and quercetin. Horm. Cancer 2013, 4(5):293-300.
90. O'Keefe B.M., Simmons N., Martin S.F. Facile access to sterically hindered aryl ketones via carbonylative cross-coupling: application to the total synthesis of luteolin. Tetrahedron 2011, 67(24):4344-4351.
91. Orhan I., Daglia M., Nabavi S., Loizzo M., Sobarzo-Sánchez E., Nabavi S. Flavonoids and dementia: an update. Curr. Med. Chem. 2015, 22(8):1004-1015.
92. Pandurangan A.K., Esa N.M. Luteolin, a bioflavonoid inhibits colorectal cancer through modulation of multiple signaling pathways: a review. Asian Pac. J. Cancer Prev. 2014, 15(14):5501-5508.
93. Pandurangan A.K., Dharmalingam P., Sadagopan S.K.A., Ramar M., Munusamy A., Ganapasam S. Luteolin induces growth arrest in colon cancer cells through involvement of Wnt/beta-catenin/GSK-3 beta signaling. J. Environ. Pathol. Toxicol. Oncol. 2013, 32(2):131-139.
94. Patil S.P., Sathaye S. Neuroprotective and neurotrophic effects of apigenin and luteolin in MPTP induced Parkinsonism in mice. Mov. Disord. 2015, 30:S301-S302.
95. Patil S.P., Jain P.D., Sancheti J.S., Ghumatkar P.J., Tambe R., Sathaye S. Neuroprotective and neurotrophic effects of apigenin and luteolin in MPTP induced Parkinsonism in mice. Neuropharmacology 2014, 86:192-202.
96. Peters N.K., Frost J.W., Long S.R. A plant flavone, luteolin, induces expression of Rhizobium meliloti nodulation genes. Science 1986, 233(4767):977-980.
97. Qiao H., Zhang X., Zhu C., Dong L., Wang L., Zhang X., Xing Y., Wang C., Ji Y., Cao X. Luteolin downregulates TLR4, TLR5, NF-κB and p-p38MAPK expression, upregulates the p-ERK expression, and protects rat brains against focal ischemia. Brain Res. 2012, 1448:71-81.
98. Rao P.S., Satelli A., Moridani M., Jenkins M., Rao U.S. Luteolin induces apoptosis in multidrug resistant cancer cells without affecting the drug transporter function: involvement of cell line-specific apoptotic mechanisms. Int. J. Cancer 2012, 130(11):2703-2714.
99. Renaud J., Nabavi S.m., Daglia M., Nabavi S.F., Martinoli M.G. Epigallocatechin-3-gallate, a promising molecule for Parkinson's disease?. Rejuvenation Res. 2015, 18(3):257-269.
100. Rodgers K.M., Hutchinson M.R., Northcutt A., Maier S.F., Watkins L.R., Barth D.S. The cortical innate immune response increases local neuronal excitability leading to seizures. Brain 2009, 132:2478-2486.
101. Ruan J.S., Zhang L., Yan L.G., Liu Y.P., Yue Z.Q., Chen L., Wang A.Y., Chen W.X., Zheng S.Z., Wang S.M., Lu Y. Inhibition of hypoxia-induced epithelial mesenchymal transition by luteolin in non-small cell lung cancer cells. Mol. Med. Rep. 2012, 6(1):232-238.
102. Saito Y., Nishio K., Ogawa Y., Kinumi T., Yoshida Y., Masuo Y., Niki E. Molecular mechanisms of 6-hydroxydopamine-induced cytotoxicity in PC12 cells: involvement of hydrogen peroxide-dependent and -independent action. Free Radic. Biol. Med. 2007, 42(5):675-685.
103. Sakai R., Yokobe S., Abe N., Miyoshi N., Murata Y., Nakamura Y. luteolin overcomes resistance to benzyl isothiocyanate-induced apoptosis in human colorectal cancer HCT-116 cells. J. Food Drug Anal. 2012, 20:389-393.
104. Scippo M.L., Argiris C., Van de Weerdt C., Muller M., Willemsen P., Martial J., Maghuin-Rogister G. Recombinant human estrogen, androgen and progesterone receptors for detection of potential endocrine disruptors. Anal. Bioanal. Chem. 2004, 378(3):664-669.
105. Shaikh M.F., Sathaye S. Anticonvulsant activity of Eclipta alba using experimental models of epilepsy. Epilepsia 2011, 52:262.
106. Shaikh A.M., Patil B., Shahshtry V.R., Gade J. Study of the glycoside; guteolin-7-O-beta--glucopyranoside from the flowers of Jatropha curcas (Linn.). Res. J. Biotechnol. 2008, 438-439.
107. Shaikh M.F., Tan K.N., Borges K. Anticonvulsant screening of luteolin in four mouse seizure models. Neurosci. Lett. 2013, 550:195-199.
108. Shimoi K., Okada H., Furugori M., Goda T., Takase S., Suzuki M., Hara Y., Yamamoto H., Kinae N. Intestinal absorption of luteolin and luteolin 7-O-β-glucoside in rats and humans. FEBS Lett. 1998, 438(3):220-224.
109. Small D.H., Mok S.S., Bornstein J.C. Alzheimer's disease and Abeta toxicity: from top to bottom. Nat. Rev. Neurosci. 2001, 2(8):595-598.
110. Somfai G.M., Knippel B., Ruzicska E., Stadler K., Toth M., Salacz G., Magyar K., Somogyi A. Soluble semicarbazide-sensitive amine oxidase (SSAO) activity is related to oxidative stress and subchronic inflammation in streptozotocin-induced diabetic rats. Neurochem. Int. 2006, 48(8):746-752.
111. Sosa-Ortiz A.L., Acosta-Castillo I., Prince M.J. Epidemiology of dementias and Alzheimer's disease. Arch. Med. Res. 2012, 43(8):600-608.
112. Starkey N.J.E., Drenkhahn S.K., Pompeu D., Slusarz A., Rottinghaus G.E., Lubahn D.B. Comparison of the differential estrogen receptor beta versus estrogen receptor alpha binding affinities of 3 natural isoflavone compounds (spinacetin patuletin, and luteolin) and 2 endogenous hydroxylated cholesterol derivatives (25-and 27-hydroxycholesterol): implications for hedgehog signaling in prostate cancer. Endocrinol. Rev. 2010, 31(3).
113. Sternberg Z., Chadha K., Lieberman A., Drake A., Hojnacki D., Weinstock-Guttman B., Munschauer F. Immunomodulatory responses of peripheral blood mononuclear cells from multiple sclerosis patients upon in vitro incubation with the flavonoid luteolin: additive effects of IFN-beta. J. Neuroinflammation 2009, 6:28.
114. Sun M., Zhao Y., Gu Y., Zhang Y. Protective effects of taurine against closed head injury in rats. J. Neurotrauma 2015, 32(1):66-74.
115. Taliou A., Zintzaras E., Lykouras L., Francis K. An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders. Clin. Ther. 2013, 35(5):592-602.
116. Taylor J.M., Main B.S., Crack P.J. Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease. Neurochem. Int. 2013, 62(5):803-819.
117. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991, 30(4):572-580.
118. Theoharides T.C., Doyle R. Autism, gut-blood-brain barrier, and mast cells. J. Clin. Psychopharmacol. 2008, 28(5):479-483.
119. Theoharides T.C., Angelidou A., Alysandratos K.D., Zhang B.D., Asadi S., Francis K., Toniato E., Kalogeromitros D. Mast cell activation and autism. Biochim. Biophys. Acta-Mol. Basis Dis. 2012, 1822(1):34-41.
120. Theoharides T.C., Asadi S., Panagiotidou S., Weng Z.Y. The missing link in autoimmunity and autism: extracellular mitochondrial components secreted from activated live mast cells. Autoimmun. Rev. 2013, 12(12):1136-1142.
121. Theoharides T.C., Stewart J.M., Hatziagelaki E., Kolaitis G. Brain fog, inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin. Front. Neurosci. 2015, 9:225.
122. Theoharides T.C. Luteolin as a therapeutic option for multiple sclerosis. J. Neuroinflammation 2009, 6:29.
123. Theoharides T.C. Activation of mast cells and neuroglia leads to brain inflammation inhibited by luteolin-implications for treatment of Alzheimer's and autism. Ann. Nutr. Metab. 2012, 61(4):324-325.
124. Tshikalange T., Meyer J., Hussein A. Antimicrobial activity, toxicity and the isolation of a bioactive compound from plants used to treat sexually transmitted diseases. J. Ethnopharmacol. 2005, 96(3):515-519.
125. Ulubelen A., Miski M., Neuman P., Mabry T. Flavonoids of Salvia tomentosa (Labiatae). J. Nat. Prod. 1979, 42(3):261-263.
126. Upadhyay A., Agrahari P., Singh D. A review on the pharmacological aspects of Terminalia chebula. Int. J. Pharmacol. 2014, 10(6):289-298.
127. Verbeek R., van Tol E.A., van Noort J.M. Oral flavonoids delay recovery from experimental autoimmune encephalomyelitis in SJL mice. Biochem. Pharmacol. 2005, 70(2):220-228.
128. Wancata J., Musalek M., Alexandrowicz R., Krautgartner M. Number of dementia sufferers in Europe between the years 2000 and 2050. Eur. Psychiatry 2003, 18(6):306-313.
129. Wang L.M., Xie K.P., Huo H.N., Shang F., Zou W., Xie M.J. Luteolin inhibits proliferation induced by IGF-1 pathway dependent ER alpha in human breast cancer MCF-7 cells. Asian Pac. J. Cancer Prev. 2012, 13(4):1431-1437.
130. Wang L., Li W., Garcia M., Lilly M., Mercola D., Martins-Green M. Luteolin, ellagic acid and punicic acid are natural products that inhibit prostate cancer metastasis. Carcinogenesis 2014, 35(10):2321-2330.
131. Wei G.I., Hwang L.S., Tsai C.L. Absolute bioavailability, pharmacokinetics and excretion of 5,7,3',4'-tetramethoxyflavone in rats. J. Funct. Foods 2014, 7:136-141.
132. Weng Z., Patel A.B., Panagiotidou S., Theoharides T.C. The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. J. Allergy Clin. Immunol. 2015, 135(4). 1044-1052 e1045.
133. Werner C., Engelhard K. Pathophysiology of traumatic brain injury. Br. J. Anaesth. 2007, 99(1):4-9.
134. Xie F., Lang Q.Y., Zhou M., Zhang H.X., Zhang Z.S., Zhang Y.F., Wan B., Huang Q., Yu L. The dietary flavonoid luteolin inhibits Aurora B kinase activity and blocks proliferation of cancer cells. Eur. J. Pharm. Sci. 2012, 46(5):388-396.
135. Xu J., Wang H., Ding K., Zhang L., Wang C., Li T., Wei W., Lu X. Luteolin provides neuroprotection in models of traumatic brain injury via the Nrf2-ARE pathway. Free Radic. Biol. Med. 2014, 71:186-195.
136. Xue X., Liu H., Qi L., Li X., Guo C., Gong D., Qu H. Baicalein ameliorated the upregulation of striatal glutamatergic transmission in the mice model of Parkinson's disease. Brain Res. Bull. 2014, 103:54-59.
137. Yan S.F., Ramasamy R., Naka Y., Schmidt A.M. Glycation, inflammation, and RAGE-a scaffold for the macrovascular complications of diabetes and beyond. Circ. Res. 2003, 93(12):1159-1169.
138. Yan J.Q., Wang Q., Zheng X.L., Sun H., Zhou Y.Q., Li D.X., Lin Y., Wang X. Luteolin enhances TNF-related apoptosis-inducing ligand's anticancer activity in a lung cancer xenograft mouse model. Biochem. Biophys. Res. Commun. 2012, 417(2):842-846.
139. Youdim M., Buccafusco J. CNS targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases. J. Neural Transm. 2005, 112(4):519-537.
140. Zhang Q., Wan L., Guo Y., Cheng N., Cheng W., Sun Q., Zhu J. Radiosensitization effect of luteolin on human gastric cancer Sgc-7901Cells. J. Biol. Regul. Homeost. Agents 2009, 23(2):71-78.
141. Zhang Y.C., Gan F.F., Shelar S.B., Ng K.Y., Chew E.H. Antioxidant and Nrf2 inducing activities of luteolin, a flavonoid constituent in Ixeris sonchifolia Hance, provide neuroprotective effects against ischemia-induced cellular injury. Food Chem. Toxicol. 2013, 59:272-280.
142. Zhang J., Liu M., Cui W., Yang J., Yang B. Total synthesis of luteolin. J. Chem. Res. 2014, 38(1):60-61.
143. Zhang Y.W., Zhang J.Q., Liu C., Wei P., Zhang X., Yuan Q.Y., Yin X.T., Wei L.Q., Cui J.G., Wang J. Memory dysfunction in type 2 diabetes mellitus correlates with reduced hippocampal CA1 and subiculum volumes. Chin. Med. J. 2015, 128(4):465-471.
144. Zhao Y.X., Yang G.T., Ren D.M., Zhang X.M., Yin Q.W., Sun X.F. Luteolin suppresses growth and migration of human lung cancer cells. Mol. Biol. Rep. 2011, 38(2):1115-1119.
145. Zhou P., Li L.P., Luo S.Q., Jiang H.D., Zeng S. Intestinal absorption of luteolin from peanut hull extract is more efficient than that from individual pure luteolin. J. Agric. Food Chem. 2008, 56(1):296-300.
146. Zhou Q., Yan B., Hu X.W., Li X.B., Zhang J., Fang J. Luteolin inhibits invasion of prostate cancer PC3 cells through E-cadherin. Mol. Cancer Ther. 2009, 8(6):1684-1691.
147. Zhou F.T., Qu L.N., Lv K., Chen H.L., Liu J.K., Liu X.M., Li Y.H., Sun X.C. Luteolin protects against reactive oxygen species-mediated cell death induced by zinc toxicity via the PI3K-Akt-NF-kappa B-ERK-dependent pathway. J. Neurosci. Res. 2011, 89(11):1859-1868.
148. de Lau L.M., Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol. 2006, 5(6):525-535.